Ask AI

Elevating Tardive Dyskinesia Detection and Care: Comprehensive Strategies for APP

Video
This activity is available for 1.00 CME/CE credit(s).

Released: October 20, 2026

Expiration: October 19, 2027

See Activity Collection

Early recognition of tardive dyskinesia requires healthcare professionals to identify subtle or easily overlooked movements that can affect physical functioning, psychological well-being, social engagement, and treatment adherence. This expert-led webcast explores strategies for identifying patients at risk, incorporating structured AIMS assessments into practice, differentiating TD from other drug-induced movement disorders, evaluating TD-related functional and quality-of-life impact, and evidence-based treatment approaches including VMAT2 inhibitors.

TD Care

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people at risk for developing TD (ie, treated with antipsychotics) do you provide care for in a typical week?

2.

Which best describes your practice setting?

3.

How knowledgeable do you feel regarding the safety profile of VMAT2 inhibitors in older patients?

4.

You are seeing a 74-yr-old patient with schizophrenia for the first time. He has been treated with haloperidol for over 20 yr and has multiple comorbidities, including hypertension and type 2 diabetes. His caregiver notes that he has recently become more withdrawn. What is the likelihood that a patient with lifetime exposure to a first-generation antipsychotic will develop TD?

5.

A 32-yr-old woman with bipolar disorder and generalized anxiety disorder is currently treated with quetiapine (5 yr duration) plus sertraline and propranolol. On a routine visit, she has no movement-related complaints, but you note slight movements including lip smacking and tongue movements when she is concentrating. When you mention this, she attributes it to stress.

Which would be an example of an activation maneuver useful to unmask symptoms of potential TD?

6.

A 70-yr-old man with schizoaffective disorder complains of symptoms; your AIMS assessment indicates moderate TD. He is treated with clozapine plus several medications for cardiovascular disease. You consider initiating a VMAT2 inhibitor but are concerned about safety given his comorbidities. What cardiovascular condition would be most important to consider?